Major Japanese Pharmaceutical Companies Foresee Increase In Revenue And Profits
This article was originally published in PharmAsia News
Executive Summary
Several Japanese pharma companies are predicting a rise in profits. Although Daiichi Sankyo spun off its non-drug business, it sees an increase in revenue and profits in its drug business. Astellas plans on expanding its domestic and overseas market share for its global products, such as immunosuppressant drugs and an overactive bladder treatment, and an increase in profit as a result of lower R&D expenses. Eisai is focusing on accelerating development of its Alzheimer's and anti-ulcerogenic drugs. Taisho revised its estimate upward because of a positive showing for its new products sector. Along with pipeline activities, these companies are improving cost ratios to gear up for overseas expanions in Europe and North America. (Click for more-Japanese language